Citations

Mayo Clinic

Showing 10 of 108522 citations.

Tumour cell–derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth
Haga, Hiroaki , Takahashi, Kenji , Wood, Joseph, Yan, Irene K. , Zubair, Abba, Zubair, Abba C. , Patel, Tushar

Journal of Extracellular Vesicles | January 2, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.3402/jev.v4.24900 | PMID 25557794 Get It

The contributions of mesenchymal stem cells (MSCs) to tumour growth and stroma formation are poorly understood. Tumour cells can transfer genetic information and modulate cell signalling in other cells through the release of extracellular vesicles (EVs). We examined the contribution of EV‐mediated inter‐cellular signalling between bone marrow MSCs and tumour cells in human cholangiocarcinoma, highly desmoplastic cancers that are characterized by tumour cells closely intertwined within a dense fibrous stroma. Exposure of MSCs to tumour cell–derived EVs enhanced MSC migratory capability and expression of alpha‐smooth muscle actin mRNA, in addition to mRNA expression and release of CXCL‐1, CCL2 and IL‐6. Conditioned media from MSCs exposed to tumour cell–derived EVs increased STAT‐3 phosphorylation and proliferation in tumour cells. These effects were completely blocked by anti‐IL‐6R antibody. In conclusion, tumour cell–derived EVs can contribute to the generation of tumour stroma through fibroblastic differentiation of MSCs, and can also selectively modulate the cellular release of soluble factors such as IL‐6 by MSCs that can, in turn, alter tumour cell proliferation. Thus, malignant cells can “educate” MSCs to induce local microenvironmental changes that enhance tumour cell growth.
Simulation‐based Training for Emergency Medicine Residents in Sterile Technique During Central Venous Catheterization: Impact on Performance, Policy, and Outcomes
Hoskote, Sumedh S. , Khouli, Hassan, Lanoix, Richard, Rose, Keith, Clark, Mark , Chalfin, Donald B. , Shapiro, Janet , Han, Qifa, Aqeel, Adnan

Academic Emergency Medicine | January 1, 2015 | Volume: 22 | Issue: 1 | Pages: 81-87

10.1111/acem.12551 | PMID 25556399 Get It

AbstractObjectivesCentral line–associated bloodstream infection (CLABSI) is a preventable nosocomial infection. Simulation‐based training in sterile technique during central venous catheter (CVC) placement for emergency medicine (EM) residents, and its effect on changing the medical intensive care unit (MICU) practice of routine replacement of CVCs placed under sterile technique in the emergency department (ED), has not been evaluated.MethodsEmergency medicine residents received simulation‐based sterile technique training during CVC placement between May 2008 and September 2010. Between June 2008 and January 2011, the authors reviewed records of patients who had CVCs placed in the ED under sterile technique by EM residents and were admitted to the MICU (group 1) and CVCs placed in the MICU under sterile technique by internal medicine (IM) residents (group 2). IM residents completed similar simulation‐based training before May 2008. Changes in EM residents' sterile technique performance scores were compared, as well as CLABSI rates in both groups. EM residents' CVC procedural skills were not assessed.ResultsSeventy‐six EM residents completed simulation‐based training with significant improvement in performance (median scores 13 out of 24 before training, 24 out of 24 after training; p < 0.001). CLABSI rates per 1,000 catheter‐days were 1.02 in group 1 and 1.02 in group 2 (p = 0.99). Both groups had similar demographics, acuity, and mortality (p > 0.5).ConclusionsRoutine replacement of CVCs placed in the ED under sterile technique after simulation‐based training would appear to be unnecessary. These findings demonstrate patient‐centered outcomes that are comparable for CVCs in ED‐admitted MICU patients, regardless of whether the CVC was placed in the ED or MICU.
Survival and low-grade glioma: the emergence of genetic information
Claus, Elizabeth B. , Walsh, Kyle M. , Molinaro, Annette M. , Wiemels, Joseph L. , Schildkraut, Joellen M. , Jenkins, Robert B. , Wrensch, Margaret , Wiencke, John K. , Molinaro, Annette M. , Bondy, Melissa L. , Berger, Mitchel S.

Neurosurgical Focus | January 1, 2015 | Volume: 38 | Issue: 1 | Pages: E6

10.3171/2014.10.focus12367 | PMID 25552286 Get It

Significant gaps exist in our understanding of the causes and clinical management of glioma. One of the biggest gaps is how best to manage low-grade (World Health Organization [WHO] Grade II) glioma. Low-grade glioma (LGG) is a uniformly fatal disease of young adults (mean age 41 years), with survival averaging approximately 7 years. Although LGG patients have better survival than patients with high-grade (WHO Grade III or IV) glioma, all LGGs eventually progress to high-grade glioma and death. Data from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute suggest that for the majority of LGG patients, overall survival has not significantly improved over the past 3 decades, highlighting the need for intensified study of this tumor. Recently published research suggests that historically used clinical variables are not sufficient (and are likely inferior) prognostic and predictive indicators relative to information provided by recently discovered tumor markers (e.g., 1p/19q deletion and IDH1 or IDH2 mutation status), tumor expression profiles (e.g., the proneural profile) and/or constitutive genotype (e.g., rs55705857 on 8q24.21). Discovery of such tumor and constitutive variation may identify variables needed to improve randomization in clinical trials as well as identify patients more sensitive to current treatments and targets for improved treatment in the future. This article reports on survival trends for patients diagnosed with LGG within the United States from 1973 through 2011 and reviews the emerging role of tumor and constitutive genetics in refining risk stratification, defining targeted therapy, and improving survival for this group of relatively young patients.
Malignant Bowel Obstruction in Patients With Recurrent Ovarian Cancer
Tran, Elizabeth, Spiceland, Clayton M. , Sandhu, Nicole P. , Jatoi, Aminah , Spiceland, Clayton

American Journal of Hospice and Palliative Medicine® | December 31, 2014 | Volume: 33 | Issue: 3 | Pages: 272-275

10.1177/1049909114566225 | PMID 25552305 Get It

We sought to report incidence, risk factors, and survival related to bowel obstruction in 311 ovarian cancer patients with recurrent disease. A total of 68 (22%) had a documented bowel obstruction during their cancer course, and 49 (16%) developed it after cancer recurrence. Surprisingly, 142 (45%) fit into an “unknown” category (3+ months of data lacking from last contact/death). No risk factors were identified; management included surgery (n = 21), conservative measures (n = 21), and other (n = 7). Documented bowel obstruction was not associated with a statistically significant reduction in survival after cancer recurrence. In conclusion, although bowel obstruction occurs in only a subgroup of patients with ovarian cancer and does not appear to detract from survival after cancer recurrence, limited end-of-life information may be resulting in an underestimation of incidence.
Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction
Mohammed, Selma F. , Mirzoyev, Sultan A. , Edwards, William D. , Maleszewski, Joseph J. , Redfield, Margaret M. , Hussain, Saad, Hussain, Saad Abdulrahman

Circulation | December 31, 2014 | Volume: 131 | Issue: 6 | Pages: 550-559

10.1161/circulationaha.114.009625 | PMID 25552356 Get It

Background— Characterization of myocardial structural changes in heart failure with preserved ejection fraction (HFpEF) has been hindered by the limited availability of human cardiac tissue. Cardiac hypertrophy, coronary artery disease (CAD), coronary microvascular rarefaction, and myocardial fibrosis may contribute to HFpEF pathophysiology. Methods and Results— We identified HFpEF patients (n=124) and age-appropriate control subjects (noncardiac death, no heart failure diagnosis; n=104) who underwent autopsy. Heart weight and CAD severity were obtained from the autopsy reports. With the use of whole-field digital microscopy and automated analysis algorithms in full-thickness left ventricular sections, microvascular density (MVD), myocardial fibrosis, and their relationship were quantified. Subjects with HFpEF had heavier hearts (median, 538 g; 169% of age-, sex-, and body size–expected heart weight versus 335 g; 112% in controls), more severe CAD (65% with ≥1 vessel with >50% diameter stenosis in HFpEF versus 13% in controls), more left ventricular fibrosis (median % area fibrosis, 9.6 versus 7.1) and lower MVD (median 961 versus 1316 vessels/mm 2 ) than control ( P <0.0001 for all). Myocardial fibrosis increased with decreasing MVD in controls ( r =–0.28, P =0.004) and HFpEF ( r =–0.26, P =0.004). Adjusting for MVD attenuated the group differences in fibrosis. Heart weight, fibrosis, and MVD were similar in HFpEF patients with CAD versus without CAD. Conclusions— In this study, patients with HFpEF had more cardiac hypertrophy, epicardial CAD, coronary microvascular rarefaction, and myocardial fibrosis than controls. Each of these findings may contribute to the left ventricular diastolic dysfunction and cardiac reserve function impairment characteristic of HFpEF.
Atypical Hyperplasia of the Breast — Risk Assessment and Management Options
Hartmann, Lynn C., Santen, Richard J. , Dupont, William D. , Ghosh, Karthik, Degnim, Amy C. , Ghosh, Karthik

New England Journal of Medicine | December 31, 2014 | Volume: 372 | Issue: 1 | Pages: 78-89

10.1056/nejmsr1407164 | PMID 25551530 Get It

Somatostatin Is Essential for the Sexual Dimorphism of GH Secretion, Corticosteroid-Binding Globulin Production, and Corticosterone Levels in Mice
Adams, Jessica M. , Otero-Corchón, Veronica, Hammond, Geoffrey L. , Veldhuis, Johannes D. , Qi, Nathan , Low, Malcolm J.

Endocrinology | December 31, 2014 | Volume: 156 | Issue: 3 | Pages: 1052-1065

10.1210/en.2014-1429 | PMID 25551181 Get It

AbstractDistinct male and female patterns of pituitary GH secretion produce sexually differentiated hepatic gene expression profiles, thereby influencing steroid and xenobiotic metabolism. We used a fully automated system to obtain serial nocturnal blood samples every 15 minutes from cannulated wild-type (WT) and somatostatin knockout (Sst-KO) mice to determine the role of SST, the principal inhibitor of GH release, in the generation of sexually dimorphic GH pulsatility. WT males had lower mean and median GH values, less random GH secretory bursts, and longer trough periods between GH pulses than WT females. Each of these parameters was feminized in male Sst-KO mice, whereas female Sst-KO mice had higher GH levels than all other groups, but GH pulsatility was unaffected. We next performed hepatic mRNA profiling with high-density microarrays. Male Sst-KO mice exhibited a globally feminized pattern of GH-dependent mRNA levels, but female Sst-KO mice were largely unaffected. Among the differentially expressed female-predominant genes was Serpina6, which encodes corticosteroid-binding globulin (CBG). Increased CBG was associated with elevated diurnal peak plasma corticosterone in unstressed WT females and both sexes of Sst-KO mice compared with WT males. Sst-KO mice also had exaggerated ACTH and corticosterone responses to acute restraint stress. However, consistent with their lack of phenotypic signs of excess glucocorticoids, cerebrospinal fluid concentrations of free corticosterone in Sst-KO mice were not elevated. In summary, SST is necessary for the prolonged interpulse troughs that define masculinized pituitary GH secretion. SST also contributes to sexual dimorphism of the hypothalamic-pituitary-adrenal axis via GH-dependent regulation of hepatic CBG production.
MRI of Uncommon Lesions of the Large Bowel: A Pictorial Essay
Lee, Christine U. , Glockner, James F.

Journal of Clinical Imaging Science | December 31, 2014 | Volume: 4 | Issue: No issue available | Pages: 71

10.4103/2156-7514.148265 | PMID 25806129 Get It

This pictorial essay briefly discusses methods for optimizing bowel imaging with magnetic resonance imaging (MRI) and illustrates the MRI appearance of a variety of unusual lesions involving or related specifically to the large bowel.
Prevalence of parathyroid carcinoma in 348 patients with multiple endocrine neoplasia type 1 – case report and review of the literature
Ospina, Naykky Singh , Sebo, Thomas J., Thompson, Geoffrey B. , Young, William F., Ospina, Naykky Singh , Singh Ospina, Naykky, Clarke, Bart L, Clarke, B.L. , Singh Ospina, Naykky M , Singh Ospina, Naykky

Clinical Endocrinology | December 31, 2014 | Volume: 84 | Issue: 2 | Pages: 244-249

10.1111/cen.12714 | PMID 25557532 Get It

SummaryObjectiveTo report the prevalence of parathyroid carcinoma (PC) in patients with multiple endocrine neoplasia type 1 (MEN1) and review of the literature.BackgroundPrimary hyperparathyroidism (PHP) is the most common manifestation of MEN1. The occurrence of PC in patients with MEN1 is rare and the literature regarding the clinical manifestations – including the prevalence of the disease – is scarce.ContextSingle tertiary care centre experience from 1977 to 2013.DesignElectronic search of the medical records to identify a cohort of patients with MEN1. Literature review based on current case reports.PatientsSingle case of PC in a cohort of 348 patients with MEN1. Ten cases of PC in patients with MEN1 reported in the literature.MeasurementClinical features of PC in patients with MEN1.ResultsThe prevalence of PC in 348 patients with MEN1 was found to be 0·28% (95% CI, 0–1·4%). Based on the current published cases of PC in patients with MEN1, 54·5% were women, mean age at diagnosis was 48·3 years, and the serum PTH concentrations at least four times the upper limit of the reference range in 73% of the cases.ConclusionPC in patients with MEN 1 is rare with a prevalence of 0·28%, and the clinical features are similar to PC in patients without MEN1.
Letter by Freeman et al Regarding Article, “Evidence-Based Nursing Review of Craniectomy Care”
Freeman, William D. , Smith, Christina C., Brown, Suzanne M., Freeman, William D

Stroke | December 31, 2014 | Volume: 46 | Issue: 2 | Pages: No page available

10.1161/strokeaha.114.007926 | PMID 25550367 Get It